Biosimilars hold the promise of lowering healthcare costs, but barriers like formulary delays and entrenched rebate structures continue to limit their impact. In his latest article for Pharmacy Times, Mark Campbell, PharmD, Chief Pharmacy Officer at RxBenefits, outlines the necessary changes to ensure future biosimilars gain traction in the market, including faster formulary inclusion, fostering fair competition, and empowering healthcare providers to prescribe cost-effective options to pave the way for upcoming alternatives to high-cost drugs like Stelara.
With a wave of new biosimilars on the horizon, tackling these obstacles could unlock billions in savings for employers and patients alike. Read the full article on Pharmacy Times.
